This study is being done to answer the following questions: If you have unfavorable intermediate risk prostate cancer, a low gene risk score and plan to receive radiation therapy with hormone therapy, is radiation therapy alone as effective at controlling your cancer compared to the usual combination of radiation and hormone therapy? If you have unfavorable intermediate risk prostate cancer, a higher gene risk score and plan to receive radiation therapy with hormone therapy, does adding another new hormone therapy drug to the usual combination of radiation and hormone therapy increase the length of time without your prostate cancer spreading as compared to the usual treatment? We are doing this study because we want to find out how these approaches are better, similar, or worse than the usual approach for your type of prostate cancer. The usual treatment is defined as the care most people get for prostate cancer.
You will be asked to come to the hospital for blood draws, clinic assement with your provider, imaging, complete study questionnaires, and treatment.
Darolutamide (BAY 1841788) Bayer AG is providing the study drug
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Michael Repka
Radiation Oncology - Chapel Hill
Clinical or Medical
Interventional
Cancer (Prostate)
23-1081